| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2730-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34911-1mg | |||
| Carrier-Free | NBP2-34911-100ug | |||
| Carrier-Free | NBP2-34911-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35307-10ug | |||
| Carrier-Free | NBP2-35307-1000ug | |||
| Carrier-Free | NBP2-35307-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35257-10ug | |||
| Carrier-Free | NBP2-35257-1mg | |||
| Carrier-Free | NBP2-35257-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12028-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35254-10ug | |||
| Carrier-Free | NBP2-35254-1mg | |||
| Carrier-Free | NBP2-35254-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34897-10ug | |||
| Carrier-Free | NBP2-34897-1mg | |||
| Carrier-Free | NBP2-34897-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-11965-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75198-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12021-0.025mg | |||
![SDS-Page: Recombinant Human IL-2 [ Cys Ser125]Protein [NBP3-07100] - Western blot under reducing and non-reducing conditions](http://images.novusbio.com/fullsize/Recombinant Human IL-2 [ Cys Ser125]Protein-SDS-Page-NBP3-07100-img0001.jpg "SDS-Page: Recombinant Human IL-2 [ Cys Ser125]Protein [NBP3-07100] - Western blot under reducing and non-reducing conditions")
![SDS-Page: Human CXCL10/IP-10/CRG-2 Protein [NBP2-34911]](http://images.novusbio.com/fullsize/Human-CXCL10-IP-10-CRG-2-Protein-SDS-Page-NBP2-34911-img0001.jpg "SDS-Page: Human CXCL10/IP-10/CRG-2 Protein [NBP2-34911]")
![SDS-Page: Primate IL-1 beta/IL-1F2 Protein [NBP2-35307]](http://images.novusbio.com/fullsize/Primate-IL-1-beta-IL-1F2-Protein-SDS-Page-NBP2-35307-img0001.jpg "SDS-Page: Primate IL-1 beta/IL-1F2 Protein [NBP2-35307]")
![SDS-Page: Rat IL-9 Protein [NBP2-35257]](http://images.novusbio.com/fullsize/Rat-IL-9-Protein-SDS-Page-NBP2-35257-img0001.jpg "SDS-Page: Rat IL-9 Protein [NBP2-35257]")
![SDS-Page: Rat IL-6 Protein [NBP2-35254]](http://images.novusbio.com/fullsize/Rat-IL-6-Protein-SDS-Page-NBP2-35254-img0001.jpg "SDS-Page: Rat IL-6 Protein [NBP2-35254]")
![SDS-Page: Human IL-5 Protein [NBP2-34897]](http://images.novusbio.com/fullsize/Human-IL-5-Protein-SDS-Page-NBP2-34897-img0002.jpg "SDS-Page: Human IL-5 Protein [NBP2-34897]")
![ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free [NBP2-75198] - Binding curves of NBP2-75198 (red line) and isotype control (anti-Fluorescein antibody; blue line) to an ELISA plate coated with CD27-Fc fusion protein at a concentration of 5 ug/ml. A 3-fold serial dilution from 10 mg/mL to 0.17 ng/ml of NBP2-75198 was used. CD70 (CD27-L) is the ligand for CD27. CD70 Fc-fusion protein was added to a 10mg/mL solution of NBP2-75198 starting at 10mg/mL, and then at 3-fold dilutions down to 0.17ng/mL (red line). A negative control assay using 4-1BB Fc-fusion protein was also performed (yellow line). For signal detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.](http://images.novusbio.com/fullsize/nbp2-75198_rabbit-monoclonal-cd27-tnfrsf7-antibody-rm27-3e5-chimeric-7420252228563.png "ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free [NBP2-75198] - Binding curves of NBP2-75198 (red line) and isotype control (anti-Fluorescein antibody; blue line) to an ELISA plate coated with CD27-Fc fusion protein at a concentration of 5 ug/ml. A 3-fold serial dilution from 10 mg/mL to 0.17 ng/ml of NBP2-75198 was used. CD70 (CD27-L) is the ligand for CD27. CD70 Fc-fusion protein was added to a 10mg/mL solution of NBP2-75198 starting at 10mg/mL, and then at 3-fold dilutions down to 0.17ng/mL (red line). A negative control assay using 4-1BB Fc-fusion protein was also performed (yellow line). For signal detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.")
![SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]](http://images.novusbio.com/fullsize/Recombinant-Rat-IL-10-Protein-SDS-Page-NBP2-61341-img0002.jpg "SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]")
![Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/IL-9-Antibody-D9302C12-Chimeric-Flow-Cytometry-NBP3-12021-img0001.jpg "Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.")